The GLP‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cardiovascular complications are the major causes of the mortality and morbidities in diabetic patients. The diabetic patients have an increased risk of developing atherosclerosis, which could lead to heart attack and stroke. Glucagon‐like peptide 1 (GLP‐1) receptor agonists are a class of potent anti‐glycemic agents to treat diabetes. Recently, several GLP‐1 receptor agonists have been found to have cardiovascular benefit independent of their glucose lowing ability. Liraglutide is one of clinically approved effective GLP‐1 receptor agonists. In this study, we explored the molecular mechanism of Liraglutide against oxidized low‐density lipoprotein (ox‐LDL) in cultured endothelial cells. Our data show that Liraglutide treatment ameliorates ox‐LDL caused reduction of the transcriptional factor KLF2. In the same experiment, Liraglutide also rescues ox‐LDL induced reduction of mitogen‐activated protein kinase (MAPK) kinase extracellular signal regulated kinase 5 (ERK5) phosphorylation, and blockage of ERK5 activity by its inhibitor XMD8‐92 abolishes the protection of Liraglutide on KLF2 expression. These facts suggest that the action of Liraglutide on endothelial KLF2 is dependent on ERK5. Liraglutide also recovers ox‐LDL caused reduction of endothelial tight junctions protein Occludin and ameliorates ox‐LDL induced endothelial monolayer permeability increase. On the other hand, Liraglutide inhibits ox‐LDL induced expression of vascular adhesion molecules (E‐selectin and vascular cell adhesion molecule 1), and prevents ox‐LDL induced attachment of monocytes adhesion to endothelial cells. Moreover, Liraglutide mitigates ox‐LDL triggered reduction of endothelial nitric oxide synthase (eNOS) expression and NO release. Collectively, our study provides multiple facets of the mechanisms that Liraglutide is a protective agent in endothelial cells and has the potential implication in therapeutic usage of vascular complication in diabetes patients. © 2019 IUBMB Life, 71(9):1347–1354, 2019
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The large population LEADER trial with cardiovascular outcomes as endpoint concludes Liraglutide has cardiovascular benefit for type 2 diabetes patients (27).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · cited 1×
“Liraglutide is a derivative of native GLP, and it has relative longer half-life-13 h in vivo and is a once-daily dosing drug (26).”
BackgroundLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350 · cited 1×
“Liraglutide is a GLP-1 analog which shares 97% sequence identity to native GLP-1 and its duration of action can last for more than 24 h (13).”
BackgroundShiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99 · cited 1×
“The action of GLP-1 RAs is dependent on the binding to its receptor, and GLP-1 receptor is expressed on the endothelium and contributes to varied vascular function (11, 12).”
BackgroundKushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“A number of studies has found that liraglutide prevented these AS effects of ox-LDL by preventing the inhibitory effect of the p53 protein on kruppel-like factor 2 (KLF2) of human aortic endothelial cells (114, 128).”
BackgroundJiang, H., Zhou, Y., Nabavi, S. M., Sahebkar, A., Little, P. J., Xu, S., Weng, J., & Ge, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.925923 · Cited by 323
Cong, X., & Kong, W. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109485 · Cited by 302
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“In addition to mitigating the reduction of eNOS expression and NO release, the drug caused an amelioration of increased permeability, inhibition of vascular adhesion molecules’ expression, and prevention of monocytes’ adhesion to cultured ECs [212].”
BackgroundLe, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“…the extracellular-signal-regulated kinase 5 (ERK5) pathway, GLP-1 RAs have been shown to increase Krüppel-like factor 2 (KLF2) levels and prevent inhibition of mitogen-activated protein kinase (MAPK), which causes downstream anti-inflammatory effects, including decreased leukocyte adhesion [132].”
BackgroundHullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“Moreover, liraglutide can activate ERK5 signaling in endothelial cells, mitigating endothelial dysfunction [61].”
Metadata
- Authors
- Yue, W., Li, Y., Ou, D., & Yang, Q.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2019-04-10
- Volume
- 71
- Issue
- 9
- Pages
- 1347-1354
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2938775788
- Cited by
- 60
- References
- 10
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.